ICPT · Intercept Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $88.79M | $83.72M | $67.96M | - | $77.59M | $71.76M | $88.58M | - | $92.83M | $96.58M |
| Cost of Revenue | $197.0K | $185.0K | $222.0K | - | $424.0K | $309.0K | $758.0K | - | $658.0K | $618.0K |
| Gross Profit | $88.59M | $83.53M | $67.74M | - | $77.16M | $71.45M | $87.82M | - | $92.17M | $95.96M |
| R&D | $41.51M | $37.31M | $41.71M | - | $44.03M | $44.83M | $48.09M | - | $45.05M | $37.79M |
| SG&A | $45.44M | $53.35M | $57.66M | - | $43.27M | $39.98M | $50.01M | - | $53.34M | $57.66M |
| Total Operating Expenses | $93.41M | $90.84M | $99.59M | - | $87.73M | $85.12M | $98.85M | - | $99.05M | $95.82M |
| D&A | - | - | $89.0K | - | - | - | $375.0K | - | - | - |
| Operating Income | ($4.62M) | ($7.12M) | ($31.63M) | - | ($10.14M) | ($13.36M) | ($10.27M) | - | ($6.22M) | $760.0K |
| Interest Expense | $1.80M | $2.81M | $2.81M | - | $5.24M | $6.67M | $6.67M | - | $14.10M | $12.59M |
| Income Tax | - | - | - | - | $0 | - | - | - | - | - |
| Net Income | ($2.79M) | ($5.86M) | ($32.13M) | - | $267.45M | ($7.53M) | ($17.28M) | - | ($3.63M) | ($11.09M) |
| EPS - Basic | ($0.07) | ($0.14) | ($0.77) | - | $7.80 | ($0.25) | ($0.58) | - | ($0.11) | - |
| EPS - Diluted | ($0.07) | ($0.14) | ($0.77) | - | $7.80 | ($0.25) | ($0.58) | - | ($0.11) | - |
Balance Sheet
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $102.74M | $136.23M | $61.40M | $50.52M | $113.19M | $58.02M | $48.32M | $84.71M | $68.33M | $145.62M |
| Accounts Receivable | $32.48M | $29.79M | $28.75M | $26.86M | $26.17M | $27.52M | $46.14M | $47.62M | $46.16M | $45.25M |
| Inventory | $2.65M | $6.27M | $6.46M | $6.46M | $6.27M | $6.89M | $8.26M | $8.62M | $8.78M | $9.00M |
| Accounts Payable | $10.27M | $85.0K | $12.74M | $14.23M | $21.30M | $11.67M | $10.39M | $18.13M | $14.91M | $15.09M |
| Current Assets | $383.44M | $470.77M | $490.46M | $540.13M | $545.37M | $487.01M | $477.35M | $502.29M | $496.33M | $493.11M |
| Total Assets | $393.16M | $484.63M | $504.08M | $553.71M | $559.40M | $498.60M | $503.36M | $527.02M | $523.07M | $523.22M |
| Current Liabilities | $90.84M | $187.02M | $207.12M | $230.08M | $221.58M | $151.43M | $151.04M | $166.82M | $143.85M | $145.28M |
| Long-term Debt | $223.86M | $223.60M | $223.35M | $223.10M | $222.86M | $713.86M | $716.88M | $539.78M | $530.41M | $575.82M |
| Total Liabilities | $321.32M | $417.09M | $436.90M | $460.63M | $451.73M | $868.43M | $875.12M | $710.99M | $679.10M | $726.42M |
| Stockholders' Equity | $71.84M | $67.55M | $67.19M | $93.08M | $107.68M | ($369.83M) | ($371.76M) | ($183.96M) | ($156.03M) | ($203.19M) |
| Retained Earnings | ($2.18B) | ($2.17B) | ($2.17B) | ($2.14B) | ($2.12B) | ($2.38B) | ($2.38B) | ($2.49B) | ($2.45B) | ($2.45B) |
Cash Flow
| Line item | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($51.60M) | - | - | - | ($20.12M) | - | - | - |
| Investing Cash Flow | - | - | $59.32M | - | - | - | ($14.22M) | - | - | - |
| Financing Cash Flow | - | - | ($254.0K) | - | - | - | ($318.0K) | - | - | - |
| CapEx | - | - | - | - | - | - | $7.0K | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | ($20.13M) | - | - | - |
Ratios
| Metric | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 99.8% | 99.8% | 99.7% | - | 99.5% | 99.6% | 99.1% | - | 99.3% | 99.4% |
| Operating margin | -5.2% | -8.5% | -46.5% | - | -13.1% | -18.6% | -11.6% | - | -6.7% | 0.8% |
| EBITDA margin | - | - | -46.4% | - | - | - | -11.2% | - | - | - |
| Net margin | -3.1% | -7.0% | -47.3% | - | 344.7% | -10.5% | -19.5% | - | -3.9% | -11.5% |
| Free cash flow margin | - | - | - | - | - | - | -22.7% | - | - | - |
| FCF / Net income | - | - | - | - | - | - | 1.16 | - | - | - |
| R&D / Revenue | 46.8% | 44.6% | 61.4% | - | 56.8% | 62.5% | 54.3% | - | 48.5% | 39.1% |
| SG&A / Revenue | 51.2% | 63.7% | 84.8% | - | 55.8% | 55.7% | 56.5% | - | 57.5% | 59.7% |
| Effective tax rate | - | - | - | - | 0.0% | - | - | - | - | - |
| Return on assets | -0.7% | -1.2% | -6.4% | - | 47.8% | -1.5% | -3.4% | - | -0.7% | -2.1% |
| Return on equity | -3.9% | -8.7% | -47.8% | - | 248.4% | 2.0% | 4.6% | - | 2.3% | 5.5% |
| Return on invested capital | - | - | - | - | -3.1% | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 4.22 | 2.52 | 2.37 | 2.35 | 2.46 | 3.22 | 3.16 | 3.01 | 3.45 | 3.39 |
| Quick ratio | 4.19 | 2.48 | 2.34 | 2.32 | 2.43 | 3.17 | 3.11 | 2.96 | 3.39 | 3.33 |
| Cash ratio | 1.13 | 0.73 | 0.30 | 0.22 | 0.51 | 0.38 | 0.32 | 0.51 | 0.47 | 1.00 |
| Leverage | ||||||||||
| Debt / Equity | 3.12 | 3.31 | 3.32 | 2.40 | 2.07 | -1.93 | -1.93 | -2.93 | -3.40 | -2.83 |
| Debt / Assets | 0.57 | 0.46 | 0.44 | 0.40 | 0.40 | 1.43 | 1.42 | 1.02 | 1.01 | 1.10 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -2.6x | -2.5x | -11.3x | - | -1.9x | -2.0x | -1.5x | - | -0.4x | 0.1x |
| Equity multiplier | 5.47 | 7.17 | 7.50 | 5.95 | 5.20 | -1.35 | -1.35 | -2.86 | -3.35 | -2.57 |
| Liabilities / Assets | 0.82 | 0.86 | 0.87 | 0.83 | 0.81 | 1.74 | 1.74 | 1.35 | 1.30 | 1.39 |
| Efficiency | ||||||||||
| Asset turnover | 0.23 | 0.17 | 0.13 | - | 0.14 | 0.14 | 0.18 | - | 0.18 | 0.18 |
| Inventory turnover | 0.07 | 0.03 | 0.03 | - | 0.07 | 0.04 | 0.09 | - | 0.07 | 0.07 |
| Days sales outstanding | 134d | 130d | 154d | - | 123d | 140d | 190d | - | 182d | 171d |
| Days inventory outstanding | 4908d | 12374d | 10623d | - | 5401d | 8140d | 3976d | - | 4870d | 5318d |
| Days payable outstanding | 19023d | 168d | 20953d | - | 18339d | 13780d | 5001d | - | 8270d | 8914d |
| Cash conversion cycle | -13981d | 12337d | -10176d | - | -12815d | -5500d | -835d | - | -3218d | -3425d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 14.4% | 16.7% | -23.3% | - | -16.4% | -25.7% | 8.5% | - | 16.7% | 25.0% |
| Revenue CAGR (3y) | 3.7% | 2.7% | -2.2% | - | 7.8% | 2.7% | 19.2% | - | 25.5% | 30.4% |
| Revenue CAGR (5y) | 13.6% | 14.0% | 13.6% | - | 13.4% | 18.4% | 33.3% | - | 191.0% | 193.3% |
| Gross profit growth (YoY) | 14.8% | 16.9% | -22.9% | - | -16.3% | -25.5% | 8.6% | - | 18.6% | 27.3% |
| Operating income growth (YoY) | 54.5% | 46.7% | -207.9% | - | -63.1% | - | 65.0% | - | 88.7% | - |
| Net income growth (YoY) | - | 22.1% | -85.9% | - | - | 32.1% | 57.2% | - | 94.5% | 82.5% |
| EPS growth (YoY) | - | 44.0% | -32.8% | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | 63.4% | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -33.3% | - | - | - | - | -82.0% | -85.9% | -10.3% | -19.8% | -157.9% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2021-12-31.
Product / service
$363.47M totalProduct$363.47M · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing INTERCEPT PHARMACEUTICALS against the 5 most active filers in the same SIC group.